Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.33 USD
Change Today +0.03 / 2.31%
Volume 53.1K
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

neptune tech & bioressources (NEPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/15/14 - $2.42
52 Week Low
10/14/14 - $1.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

neptune tech & bioressources (NEPT) Related Businessweek News

No Related Businessweek News Found

neptune tech & bioressources (NEPT) Details

Neptune Technologies & Bioressources Inc., a biotechnology company, focuses on the research, development, and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. It produces marine-derived omega-3 polyunsaturated fatty acids, including Neptune Krill Oil (NKO), a dietary supplement for heart, joint, women, and brain health; ECOKRILL Oil, a generic krill oil; Rimfrost Oil, a generic krill oil; and Neptune Krill Aquatein, a protein ingredient used in the production of nursing feed for young animals, as well as new formulations derived from NKO, including NKO Beat, which targets heart and circulation health, NKO Flex, which targets bone and joint health, and NKO Focus, which targets brain and vision health. The company is also developing CaPre for the treatment of patients with severe hypertriglyceridemia and mild to moderate hypertriglyceridemia; and ONEMIA, a purified omega-3 phospholipids concentrate derived from krill oil with lower levels of phospholipids, eicosapentaenoic acid, and docosahexaenoic acid content, as well as researches, develops, and commercializes active pharmaceutical ingredients for the management of neurodevelopmental, memory, concentration, learning, and neurological disorders from prevention to treatment. Neptune Technologies & Bioressources Inc. sells its products in Canada, the United States, France, Belgium, Australia, and other countries. The company was founded in 1925 and is headquartered in Laval, Canada.

122 Employees
Last Reported Date: 07/13/15
Founded in 1925

neptune tech & bioressources (NEPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$24.5K
Head of Strategic Development
Total Annual Compensation: C$205.8K
Chief Operating Officer of Acasti
Total Annual Compensation: C$219.6K
Consulting Medical Science Liaison
Total Annual Compensation: C$236.9K
Compensation as of Fiscal Year 2015.

neptune tech & bioressources (NEPT) Key Developments

Neptune Technologies & Bioressources Inc. and Acasti Pharma Inc. Announce Appointment of Mario Paradis as Chief Financial Officer, with Effective from August 24, 2015

Neptune Technologies & Bioressources Inc. and Acasti Pharma Inc. announced the appointment of Mario Paradis as chief financial officer (CFO), starting August 24, 2015. Mr. Paradis was formerly vice president and chief financial officer at Atrium. Prior to this, he held roles of increasingly authority at Aeterna Zentaris, most notably as vice president finance and administration & corporate secretary. Mr. Paradis began his career at PricewaterhouseCoopers (PwC), where he successfully held senior positions primarily in audit and tax.

Neptune Technologies & Bioressources, Inc. Reports Company and Consolidated Earnings Results for the First Quarter Ended May 31, 2015

Neptune Technologies & Bioressources, Inc. reported company and consolidated earnings results for the first quarter ended May 31, 2015. For the quarter, on company basis, the company reported revenues of $2,699,000 versus $3,635,000 a year ago. Adjusted LBITDA was $3,206,000 versus $3,766,000 a year ago. Net loss was $4,564,000 versus $5,702,000 a year ago. For the quarter, on consolidated basis, the company reported revenues of $2,704,000 compared to $3,691,000 a year ago. Adjusted LBITDA was $5,168,000 versus $5,772,000 a year ago. Net loss was $4,966,000 versus $4,368,000 a year ago. Loss from operating activities was $6,185,032 against $8,040,218 a year ago. Loss before income taxes was $4,965,733 against $4,123,363 a year ago. net loss attributable to owners of the corporation was $4,434,008 or $0.06 per basic and diluted share against $4,682,872 or $0.06 per basic and diluted share a year ago. Cash flows used in operating activities were $2,959,697 versus cash flows from operating activities of $1,152,983 a year ago. Acquisition of property, plant and equipment was $526,409 versus $9,667,921 a year ago. Acquisition of intangible assets was $7,668 versus $6,322 a year ago.

Neptune Technologies & Bioressources, Inc. to Report Q1, 2016 Results on Jul 13, 2015

Neptune Technologies & Bioressources, Inc. announced that they will report Q1, 2016 results at 5:00 PM, Eastern Standard Time on Jul 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEPT:US $1.33 USD +0.03

NEPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apator SA 32.50 PLN +1.30
Badger Meter Inc $58.50 USD +0.23
Enzymotec Ltd $9.22 USD +0.12
Itron Inc $29.64 USD +0.14
Targeted Medical Pharma Inc $0.03 USD -0.005
View Industry Companies

Industry Analysis


Industry Average

Valuation NEPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.2x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPTUNE TECH & BIORESSOURCES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at